OPKO Health - OPK Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12 month target prices for OPKO Health's stock. Their OPK share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 159.3% from the stock's current price.
View analysts price targets for OPK or view top-rated stocks among Wall Street analysts.

OPKO Health's stock was trading at $1.25 on January 1st, 2023. Since then, OPK stock has increased by 8.0% and is now trading at $1.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our OPK earnings forecast.

OPKO Health, Inc. (NASDAQ:OPK) released its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). The biotechnology company had revenue of $185.40 million for the quarter, compared to the consensus estimate of $168.21 million. OPKO Health had a negative trailing twelve-month return on equity of 15.77% and a negative net margin of 32.70%. The firm's revenue was down 53.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.11) EPS.

ETFs with the largest weight of OPKO Health (NASDAQ:OPK) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), VanEck Israel ETF (ISRA), iShares U.S. Healthcare Providers ETF (IHF) and iShares Biotechnology ETF (IBB).

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

OPKO Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (1.16%), Geode Capital Management LLC (1.03%), Charles Schwab Investment Management Inc. (0.57%), Millennium Management LLC (0.48%), Norges Bank (0.42%) and Deutsche Bank AG (0.30%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends.

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPK stock can currently be purchased for approximately $1.35.

OPKO Health (NASDAQ:OPK) has a market capitalization of $1.04 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $-328,400,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

The company employs 4,196 workers across the globe.

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.